Hengrui Pharma Shares Rise on $2.6 Billion Obesity Drug Deal with Novo Nordisk

Shares of Jiangsu Hengrui Pharmaceuticals (1276.HK) rose in Hong Kong trading on Tuesday after the company announced a licensing agreement with Novo Nordisk for its experimental oral obesity and diabetes treatment, a deal potentially worth up to $2.6 billion.

Details of the Agreement

Under the terms of the deal, Novo Nordisk will gain exclusive rights to develop, manufacture, and commercialize the drug candidate, HRS-1596, globally, with the exception of mainland China, Hong Kong, Macao, and Taiwan, where Hengrui retains the rights.

The financial structure includes a $300 million upfront payment to Hengrui. The Chinese drugmaker is also eligible for additional development, regulatory, and commercial milestone payments that could take the total value to $2.6 billion, along with tiered royalties on net sales in the licensed territories.

The transaction is subject to U.S. antitrust clearance and other customary closing conditions and is expected to be finalized in the fourth quarter of 2026, according to the announcement.

Strategic Importance and Drug Profile

Ad

HRS-1596 is a Phase 1-ready GLP-1/GIP dual receptor agonist designed for potential once-weekly oral dosing. According to Hengrui, the drug is intended to support weight reduction and glucose control through mechanisms including appetite suppression and improved insulin sensitivity.

Hengrui has already received approval in China to begin Phase 1 trials for weight management and type 2 diabetes. For Novo Nordisk, a market leader in injectable weight-loss treatments, the deal adds a promising oral candidate to its pipeline as competition in the lucrative obesity drug market intensifies.

Market Reaction

Investors responded positively to the news, sending Hengrui's Hong Kong-listed shares up 1.5% to close at HK$45.44 on Tuesday. The stock's performance significantly outpaced the broader market, as the benchmark Hang Seng Index fell 1% during the same trading session.